Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.15
+0.09 (1.78%)
Oct 9, 2025, 11:51 AM EDT - Market open
Taysha Gene Therapies Employees
Taysha Gene Therapies had 73 employees as of December 31, 2024. The number of employees increased by 21 or 40.38% compared to the previous year.
Employees
73
Change (1Y)
21
Growth (1Y)
40.38%
Revenue / Employee
$110,932
Profits / Employee
-$1,270,137
Market Cap
1.40B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 73 | 21 | 40.38% |
Dec 31, 2023 | 52 | -13 | -20.00% |
Dec 31, 2022 | 65 | -113 | -63.48% |
Dec 31, 2021 | 178 | 140 | 368.42% |
Dec 31, 2020 | 38 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TSHA News
- 3 hours ago - Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - GlobeNewsWire
- 3 days ago - Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential - Seeking Alpha
- 5 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Top 2 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 7 days ago - Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 - GlobeNewsWire